Physician profile
Atif Qureshi
NPI 1477614303
$9,335.19
in general payments reported to CMS, 2019-2025
28 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $5,353 · 2024: $1,343 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692 · Education: $3,013 · Travel and Lodging: $2,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,692.40 |
| Education | $3,013.20 |
| Travel and Lodging | $2,629.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,097.89 | 2023-2025 | Ion, Da Vinci Surgical System |
| Electromed, INC. | $839.99 | 2023-2025 | Smartvest |
| Inspire Medical Systems, INC. | $712.62 | 2023-2025 | Inspire |
| Cook Medical LLC | $549.91 | 2025 | Blue Rhino, Echotip Procore |
| Glaxosmithkline, LLC. | $318.96 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $289.98 | 2023-2025 | Airsupra, Breztri |
| Coaptech, INC. | $257.96 | 2025 | Puma System |
| Pulmonx Corporation | $155.50 | 2023-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Regeneron Healthcare Solutions, INC. | $132.84 | 2023-2025 | Dupixent |
| Olympus America INC. | $127.47 | 2024-2025 | Spiration Valve System |
| Shionogi INC | $125.91 | 2023-2025 | Fetroja |
| Actelion Pharmaceuticals US, INC. | $123.74 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| La Jolla Pharmaceutical Company | $109.96 | 2025 | Giapreza |
| Genzyme Corporation | $83.11 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.77 | 2023-2025 | Ofev |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $44.96 | 2025 | Brinsupri, Arikayce |
| Boston Scientific Corporation | $32.20 | 2024 | |
| Pinnacle Biologics, INC | $31.41 | 2024 | Photofrin |
| Tactile Systems Technology INC | $30.36 | 2023 | Flexitouch Plus, Entre Plus |
| Medtronic, INC. | $29.18 | 2023 | Illumisite |
| Resmed Corp | $27.68 | 2024 | |
| Mallinckrodt Hospital Products INC. | $27.54 | 2025 | Acthar |
| Abbvie INC. | $26.77 | 2023 | |
| United Therapeutics Corporation | $26.57 | 2024 | Tyvaso |
| Vapotherm INC | $23.19 | 2023 | Vapotherm |
| Verona Pharma, INC. | $22.24 | 2025 | Ohtuvayre |
| Pharming Healthcare, INC. | $18.00 | 2023 | Ruconest |
| Philips North America LLC | $17.48 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.